Lymphoproliferative Disorder Treatment Market Size

  • Report ID: 2777
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Lymphoproliferative Disorder Treatment Market Size

Lymphoproliferative Disorder Treatment Market size was over USD 5.69 billion in 2024 and is projected to reach USD 13.22 billion by 2037, witnessing around 6.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of lymphoproliferative disorder treatment is evaluated at USD 6.32 billion.
 

The growth of the market can be attributed to the increasing number of lymphoproliferative disorders such as leukemia and lymphoma throughout the world. For instance, in 2020, the frequency of leukemia mortality in Spain was estimated to be around 4365 individuals. Further, the growing awareness in people regarding lymphoproliferative disorders, along with the surge in Sezary syndrome, T-cell prolymphocytic leukemia, adult T-cell leukemia-lymphoma, and big granulated lymphocyte leukemia is also estimated to skyrocket the growth of the market as these all conditions are related with the T-cell chronic lymphoproliferative disorders.

In addition to these, factors that are believed to fuel the market growth of lymphoproliferative disorders include the rise in organ transplantation cases throughout the world. Since the process of organ transplantation is raising the risk of post-transplant lymphoproliferative disorder (PTLD). For instance, more than 150,409 organ transplants took place globally in 2021. Additionally, the growing demand for effective treatments and therapies, coupled with the substantial expansion in research and development activities are also projected to drive the market growth further during the projected time frame.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2777
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of lymphoproliferative disorder treatment is evaluated at USD 6.32 billion.

The lymphoproliferative disorder treatment market size was over USD 5.69 billion in 2024 and is projected to reach USD 13.22 billion by 2037, witnessing around 6.7% CAGR during the forecast period i.e., between 2025-2037. Worldwide expanding prevalence of lymphoma cases, rise in the cases of chronic lymphocytic leukemia (CLL), and an upsurge in novel targeted treatments will boost the market growth.

North America industry is anticipated to hold largest revenue share of 45% by 2037, propelled by increasing frequency of the lymphoproliferative disorder in the region along with an increase in focus on research and development for the effective treatment of such disorders.

The major players in the market are Atara Biotherapeutics, Inc., Merck & Co., Inc., Bristol Myers Squibb Company, Genentech, Inc., ADC Therapeutics SA, AbbVie Inc., Novartis AG, Pfizer Inc., AstraZeneca, Gilead Sciences, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample